Transthoracic Echocardiography: After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
Study summary
This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System. 579 patients with valvular AF complicated with previous AF-related embolic events (including ischemic stroke, TIA and systemic embolism) were enrolled at about 20 study sites nationwide. The baseline data, operation process and relevant follow-up information of subjects were recorded at 7 months after operation or before discharge and at 1, 3, 6, 12 and 24 months after operation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years, male or female;
* Patients who are able to understand the purpose of the study, voluntarily participate in and sign the informed consent form (ICF), and are willing to complete the follow-up as required by the protocol;
* Indications for left atrial appendage closure;
* Patients with non-valvular AF complicated with previous AF related embolic event and meeting one of the following conditions;
1. HAS-BLED bleeding risk score ≥ 3 points;
2. Not suitable for long-term oral anticoagulant therapy;
3. Poor compliance with oral anticoagulants;
4. CHA2DS2-VASc score ≧ 2 points;
Exclusion Criteria:
* Valvular AF (after moderate to severe mitral stenosis or mechanical valve replacement)
* Initial AF, reversible AF with clear cause
* Presence of adherent thrombus in the left atrium or left ventricular aneurysm thrombus
* ST elevation myocardial infarction, ≤ 3 months
* Grade-IV of Cardiac Function (NYHA)
* Allergy or contraindication to metal nitinol, aspirin, clopidogrel, heparin, and other anticoagulants
* Pregnant or with plan of pregnancy during the study
* Participation in another drug or medical device clinical trial or study that has not been completed
* Experience new stroke or TI within 30 days or major bleeding events within 14 days
* Contraindication to LAA closure or deemed unsuitable for study participation by the investigator
* Had a definite thromboembolic event
Primary outcome measure(s)
Incidence of new ischemic stroke, systemic embolism, and cardiac death 12 months after operation — 12 months Ischemic stroke, systemic embolism, and cardiac death events
Incidence of major bleeding events (intracranial or gastrointestinal, or any bleeding requiring transfusion of ≥ 2 units of red blood cells) at 12 months after operation — 12 months Bleeding events
Trial sites (5)
Facility
City
Region
Status
Qilu Hospital of Shandong University
Jinan
Shandong
Recruiting
Shanghai Songjiang District Central Hospital
Shanghai
Shanghai Municipality
Recruiting
Sichuan Mianyang 404 Hospital
Mianyang
Sichuan
Recruiting
The first Affiliated Hospital of WMU
Wenzhou
Zhejiang
Recruiting
The Second Affiliated Hospital and Yuying Children's Hospital of WMU
Wenzhou
Zhejiang
Recruiting
More Lifetech Scientific (Shenzhen) Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.